y 27632 has been researched along with Diabetic Angiopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alokam, R; Mishra, RK; Sriram, D; Yogeeswari, P | 1 |
| Hirose, A; Mori, H; Okada, Y; Tanaka, Y; Tanikawa, T | 1 |
1 review(s) available for y 27632 and Diabetic Angiopathies
| Article | Year |
|---|---|
Potential role of Rho kinase inhibitors in combating diabetes-related complications including diabetic neuropathy--a review.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Humans; Mice; Oxidative Stress; Pyridines; Rats; rho-Associated Kinases; Sexual Dysfunction, Physiological; Signal Transduction; Vasodilator Agents | 2013 |
1 other study(ies) available for y 27632 and Diabetic Angiopathies
| Article | Year |
|---|---|
Advanced glycation end products increase endothelial permeability through the RAGE/Rho signaling pathway.
Topics: Actins; Amides; Capillary Permeability; Cells, Cultured; Cytoskeleton; Diabetic Angiopathies; Endothelium, Vascular; Glycation End Products, Advanced; Humans; Pyridines; Receptor for Advanced Glycation End Products; Receptors, Immunologic; rhoA GTP-Binding Protein; Serum Albumin, Bovine; Signal Transduction | 2010 |